Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Ipratropium

Criteria

Inclusion Criteria:

• Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease

• Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion

Exclusion Criteria:

• Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg